CA1266887A - Electrochemical controlled release drug delivery system - Google Patents
Electrochemical controlled release drug delivery systemInfo
- Publication number
- CA1266887A CA1266887A CA000495562A CA495562A CA1266887A CA 1266887 A CA1266887 A CA 1266887A CA 000495562 A CA000495562 A CA 000495562A CA 495562 A CA495562 A CA 495562A CA 1266887 A CA1266887 A CA 1266887A
- Authority
- CA
- Canada
- Prior art keywords
- electrode
- polymer
- charged
- current
- polymers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/07—Microporous membranes
Abstract
Abstract of the Invention A method is disclosed for the controlled delivery of an ionic bioactive chemical into a physiological medium comprising ionically binding the chemical to redox sites on a charged polymer and releasing the bound chemical into the medium by neutralizing the charge on the polymer.
Description
~266887 ELECTROCHEMICAL CONTROLLED RELEASE
DRUG DELIVERY SYSTEM
U.S.P.H.S. and N.S.F. Support This invention was made with Government support under Contract Number 5-R01-GM-24493, awarded by the U.S.
Public Health Service and Contract Number CHE-8203493, awarded by the National Science Foundation. The Government has certain rights in the invention.
Background of the Invention The controlled release of bioactive substances such as drugs has become an important mode of treatment for many diseases and disorders. Pharmaceutical manufacturers have introduced many products which are designed to gra-dually release bioactive substances at a therapeutically-useful rate and to spatially target the release. For example, the release rate may be controlled mechanically by a valving system, or physically, as by slow drug diffusion through protective encapsulation.
Iontophoresis is an electrochemical process which has found limited utility for the controlled application of charged agents such as metal ions, analgesics and anesthe-tics to afflicted bodily areas such as infla~ed joints.
Iontophoresis utilizes direct electrical current to drive ionized chemicals through the intact skin. For example, in aqueous media, sodium salicylate disassociates into ions.
The salicylate ions responsible for the analgesic action of the salt are negatively charged. Accordingly, these active species can be driven through the skin by the repelling action of a cathodic current which is applied to a reser-voir containing the active species. Thus, when ion-. ~
~26S887 tophoresing salicylate through the skin, the electrodecontacting the salicylate solution must be connected to the positive pole of a battery while the counter-electrode which contacts the skin at some remote point is connected to the negative pole to provide a return path for the current. Simple circuits effective to conduct ion-tophoresis are disclosed in U.S. Pat. No. 3,991,755.
However, special difficulties are encountered in therapeutic or experimental situations where it is desired to release discrete units of highly active agents in vivo.
For example, in neuroscience, it is important to be able to deliver neurotransmitters or drugs to specific locations at specific times. In this way, the effect of these com-pounds on single neurons can be studied. Iontophoresis hasbeen employed for drug delivery at the single neuron level, whereby a solution of an active electrolyte is placed in a micropipet and then "phoresed" out with a small current.
Although widely used, this technique suffers from a number of disadvantages, primarily related to quantification control. It is also necessary to apply the active substance in combination with a relatively large quantity of a carrier liquid to the area to be treated or tested.
One electrochemical alternative to iontophoresis is presented by L. L. Miller et al. in Neuroscience Letters, 35, 101 (1983? and J. Amer. Chem. Soc., 105, 5271, 5278 ~1983), who disclose electrodes which are used to deliver the neutral neurotransmitters dopamine (3, 4-dihydroxy-phenethylamine), glutamic acid and gamma-amino-butyric acid from their surfaces in response to an electri-cal signal. A compound electrode was constructed by coating an inert electrode with a polystyrene-based polymer film having the neurotransmitter covalently bound to the polymer backbone through an amide linkage. At sufficiently negative potentials, cathodic reduction cleaved the amide ~.2~8fl7 --3~
bond and released the neurotransmitter into a small volume of aqueous buffer. The released amine was detected at a second electrode by its electrochemical oxidation or alter-natively, analyzed by HPLC. Although this method permitted the release of a bioactive agent into a physiological medium, the amounts released at neutral pH were very low, and could not be appreciably increased by increasing the amount of loaded polymer on the electrode, due to slow charge propagation within the film.
The use of such polymers for drug delivery is disadvantageous, since a separate chemical synthesis is required to incorporate the active species into the polymer. Furthermore, polymers bearing covalently-bound drugs cannot be easily reloaded once the drug has been released from the polymeric matrix. Therefore, a need exists for a electrochemical method for the controlled delivery of charged bioactive chemical species from an electrode into physiological media such as blood, lymph, spinal fluid and the like.
8rief Description of the Invention The present invention is directed to controlled release drug delivery systems which employ an electrode comprising a polymer which can be electrochemically cycled between the charged and the neutral, or insulating states.
In the charged, or ionic state, the polymer can be loaded with bioactive counterions. When the charge on the polymer is neutralized or reversed, the counterions are released into the surrounding medium and become available to perform their intended function, e.g. to exert their phar-macological activity.
In practice, a body of the conductive polymer can be employed to form the active portion of a working electrode. The polymer is then charged cathodically or anodically while in contact with an aqueous medium con-i266a87 taining the desired drug counterion causing it toionically-bind a pharmaceutically-effective amount of the counterions. The drug-loaded electrode is then contacted with a physiological medium. As used herein, the term phy-siological medium is intended to refer to an electrolyticsolution which is either a naturally-occurring body fluid such as blood, lympht cerebrospinal fluid or the like, or which is formulated to approximate the properties of such fluids. For example, the electrode may be implanted in a natural or artifically-formed body cavity or placed in con-tact with the skin, mucous membranes or the like. The drug counterions can then be released in vivo in a controlled fashion by one or more quantified current pulses.
For example, these polymers can be loaded with anionic compounds which are bioactive, such as amino acids, by converting the polymer into the oxidized or electroposi-tive state with an anodic current in the presence of dissolved amino acid carboxylate salts. once loaded, one or more cathodic pulses can be employed to electrically neutralize the polymer, resulting in the release of all or a part of the bioactive counteranions into the desired medium. The polymer can be removed from the delivery locale, reloaded and reused if desired. The unit dosage of the bioactive compound can be controlled by adjusting para-meters such as the release pulse strength and duration, theloading concentration and the electrode conformation and position.
1266a87 -4a-BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a simplified illustration of one embodiment of a drug delivery system of the present invention.
Fig. 2 is a simplified illustration of an embodiment of a self-contained drug system of the present invention.
Fig. 3 depicts cyclic voltammograms recorded for an electrode comprising a conductive polypyrrole film, with and without bound ferricyanide.
Fig. 4 is a graphic depiction of the profile of ferri-cyanide release from an electrode comprising a conductivepolypyrrole film.
Detailed Description of the Invention Pre~aration and Loadin~ of Electroactive Polvmers Polymers useful in the present invention are ~hose organic or organometallic polymers which (a) comprise functional groups which can be electroclemically cycled between the charged and neutral states and (b) possess the , .
:. ', :
~266887 physical proper~ies required for use as working electrodes.
These polymers are preferably stable in air and water, highly conductive and processable.
In the charged state, these polymers can attract and retain oppositely-charged, pharmaceutically-effective amounts of bioactive chemical species. The ionically-bound species can be released from the polymeric matrix when the polymeric charge is neutralized. For example, polymers which comprisè cationic sites in the charged state can be loaded with bioactive anions which are delivered by employing a cathodic current to neutralize the positively charged polymer, while polymers which comprise anionic sites when charged can be used to bind and release active species which are cationic.
Such charged polymers may be considered as belonging to two broad classes: (a) those comprising redox sites which are covalently bound to an electrically inac-tive backbone, such as poly(vinylferrocene); and (b) those having redox sites integrally-incorporated into the poly-meric backbone. The latter type will be referred to herein - as "conductive polymers". For a general discussion of t these two classes of charged polymers, see L. R. Faulkner, Chem. Eng. News (Feb. 27, 1984) at pages 31-35.
Conductive polymers can be switched from the charged (conductive) and nonconducting (neutral) states by employing an electric current to alternately reduce and oxidize the polymer chain. Although the redox sites on polymers of type (a) can also be electrochemically oxidized and reduced, these polymers cannot readily pass current by - electron transfer along the back-bone. Conductive polymers, on the other hand, permit direct electron transfer along the polymeric chains, pre-ferably vla a pi-electron network. When such polymers are electrically neutral, the bonding states in the pi-electron ., .~
~, ~
,,t.~
~2668~7 network are full and electronic conductivity is very low.
The removal of pi-electrons creates cationic vacancies that permit current to ~low along the chains, while addition of pi-electrons to vacancies in neutral systems can produce anionic sites.
Since these polymers are essentially metallic in character, they can be designed to bear high charge den-sities and exhibit efficient charge transfer. Furthermore, they need not be bound to a conductive electrode surface in order for the redox sites to be charged and discharged, but can be formed into free-standing bodies which can function as working electrodes when connected to a current source.
Cationic charged polymers such as those comprising unsaturated carbocyclic or heterocyclic rings such as phenyl, pyrrole, pyridyl, cyclopentadienyl and thiafulvalenyl can be used in the invention. Preferably the rings will be linked into a continuous conjugated, pi-electron network, such as those present in polyaromatic or poly-(pseudo-aromatic) systems. One preferred class of conductive polymer is the polypyrroles, which are formed by the electrochemical oxidation of a pyrrole as described by A. F. Diaz et al. in J. Chem. Soc. Chem. Commun., 635, 854 (1979).
Polythiophene and several beta-substituted polythiophenes have been prepared by electrochemical oxida-tion and polymerization of their respective monomers.
These polymers can be repeatedly cycled between a conduc-tive oxidized state and a semi-conductive neutral state.
See G. Tourillon, J. Electroanal. Chem., 161, 51 (1984).
Although their stability in aqueous media indicates that these polymers might be useful to deliver anionic drugs, their high oxidation potentials (greater than 0.70V vs.
SCE) would eliminate the delivery of drugs that are electroactive in this potential region. The beta-substituted-thiophene, poly-3-methoxythiophene was prepared i26~;a87 and found to possess a significantly lower oxidation poten-tion. This material can be employed to deliver anions such as amino acid carboxylates according to the method of this invention.
Other conductive polymers useful to bind and release anions include substituted poly(pyrroles), substi-tuted polythiophenes and similar poly(heterocyclic) materials. Other useful conductive polymers include polyanilines, poly(thiophenols), poly(aromatics) or polyacetylenes. For example, see Chem Eng. News (Sept. 10, 1984) at pages 38-39. Conductive polymers useful for the delivery of cations can also come from the classes of polyacetylenes as well as polyaromatics or poly(heteroaromatics). For example, poly(9-phenylquino-line) would be charged negatively to hold cations, thendischarged.
Redox polymers of the type (a) which can be used to deliver bioactive anionic species include polymers holding a variety of cationic metal complexes either electrostatically or covalently. Examples include organic polymers with pendant ligands such as cyclopentadienyl, pyridine, bipyridine, tripyridine, primary amines, porphyrins, phthalocyanines and related macrocyclic ligands. These ligands can bind a wide variety of metal ions including iron, cobalt, ruthenium, osmium which are capable of rapid electron transfer reactions between the redox centers. Organic polymers which could be used as anion delivery agents include those with pendant groups that are relatively stable in both the oxidized and reduced forms, like tetrathiofulvalene, aromatic diamines, cationic dyes such as those from the classes thiazines, diazines, oxazines, triarylmethanes, cyanines, mercocyanines and the like. Polymers of type (a) useful for cation delivery include metal complexes with a net negative charge like sulfonated complexes or oxyanions like the conjugate anion ~z66a~37 of a hydroquinone or an enolate. Carboxylated or sulfo-nated aromatics could also be useful, especially when the aromatic moiety is substituted by nitro, carbonyl, or sulfonyl. Anionic dyes of interest may be selected from anionic cyanines, oxonoles, quinones, and the like.
The charged polymers can be employed to form working electrodes by electrochemically oxidizing or reducing a solution of appropriate monomer so as to deposit a coating of the charged polymer on the surface of a con-ventional electrode. If the monomer can be polymerized inthe presence of the desired counterion, it will be depo-sited in the loaded condition. If the monomer will not polymerize electrochemically in the presence of the desired counterion, the undesired counterion may be exchanged for the desired species by cycling the polymeric electrode bet-ween the neutral and charged state in contact with a medium containing an excess of the desired counterions. In this manner, the undesired ions are forced out and replaced with the desired ions.
Working electrodes comprising the present charged polymers can be formed in a wide variety of sizes, from microelectrodes of about 1 uM2 to electrodes designed to encompass an inflamed joint or to cover a large area of a patient's skin. In many cases it will be desirable to coat inert substrates of high surface area with the chargedpolymer, in order to increase the reservoir of the active species bound thereto. Implantable electrodes, or those designed for parenteral drug delivery can be fabricated from polymer coated screens or mesh, or could consist essentially of appropriately-shaped bodies of the conduc-tive polymeric material. The screens or mesh may be com-posed of a wide variety of conducting materials including metals or carbon fibers.
Especially preferred polymers for use in the pre-sent invention are those which are soluble in organic ~266aa7 solvents in either the charged or neutral state. Thesepolymeric solutions can be used to form films of controlled thickness by applying coatings of the solutions to ccnduc-tive electrode substrates, as by dip- or spin coating and then evaporating the carrier solvent. For example, the reduced form of poly-3~methoxythiophene is soluble in ace-tonitrile, methylene chloride, acetone and dimethyl for-mamide (DMF) while the oxidized form is soluble in DMF.
Bioactive Counterions The present drug-delivery method is generally applicable to the release of ionic materials such as orga-nic cations and anions. Anionic bioactive species useful as counterions include the pharmaceutically-acceptable salts of carboxylates, phosphates, sulfates, bisulfites, and the salts of acidic N-H moieties such as amides. Many useful drugs containing these functional groups are commer-cially available as their water-soluble alkali metal or alkaline earth metal salts, most commonly as sodium, lithium, potassium, magnesium or calcium salts.
Useful bioactive organic carboxylate salts - include sodium ethacrynate, levothyroxine sodium, valproate sodium, magnesium salicylate, clorazepate sodium, sodium folate, leucovorin calcium, sodium ascorbate, cephaprin sodium, cephalothin sodium, penicillin G potassium, dextrothyroxine sodium and the carboxylate salts of amino acids. Many carboxylic acid-containing drugs can be con-verted into pharmaceutically-acceptable water-soluble salts by conventional techniques, including aspirin, prostaglan-dins, retinoic acid, furosemide, tricrynafen, probenicidand the like.
Also useful as anionic counterions are phosphate salts such as cortisol sodium phosphate, menadiol sodium phosphate, etidronate disodium phosphate, triclofos sodium and the like; sulfates such as estrone potassium sulfate ~z668a7 and heparin sodium; bisulfates such as menadione sodium bisulfite and the salts of acidic amines such as purines and amides, including sulfacetamide sodium, tolbutamide sodium, sulfadiazine sodium and the salts of aminophylline, theophylline and the like.
Bioactive cationic species include the pharmaceutically-acceptable salts such as the halide, nitrate and methylsulfate salts of quaternary amines and charged sulfur and nitrogen-containing heterocyclic drugs, such as those comprising thiazinium, pyridinium, pyrrolidi-nium, thiazolium or piperidinium salts. Drugs comprising quaternary amines include gallamine triethiodide, meto-curine iodide, hexafluorenium bromide, decamethonium bro-mide, pancuronium bromide, succinyl choline chloride, neostigmine bromide, demacarcium bromide, amberonium chloride, diphemanil methyl sulfate, choline chloride, and the like. Useful heterocyclic salts include thiamine nitrate, methylene blue, trimethaphan camsylate, cetylpyri-dinium chloride and pyridostigmine bromide.
Neutral, pharmacologically-active species may also be loaded and released via the electroactive polymers if they are first modified to introduce suitable ionic functional groups, such as the above-mentioned phosphates, sulfates, quaternarized nitrogen and the like. Techniques for introducing such polar groups are well-known and widely-employed to increase the water-solubility of drugs which are nonsoluble or only sparingly soluble in water, so that they may be orally administered. Such techniques include the conversion of hydroxyl groups to halides and then to phosphonoxy or phosphinoxy groups, and the conver-sion of hydroxyl groups to the salts of half esters.
Bisulfites may be formed by the conjugate addition of bisulfite salts to alpha, beta-unsaturated ketones, and amines may be quaternized with alkyl halides.
Controlled Dru~ Release Systems Devices useful for the controlled delivery of bioactive ions into physiological media such as mammalian fluids or tissues, are schematically depicted in FIGS . 1 and 2.
In the simplified form illustrated in FIG. 1, the drug delivery device incorporates working electrode S
which, as illustrated, comprises a coating of the charged polymer 6 on an inert conductive body 7. Body 7 may be formed of any physiologically inert substance, e.g. glassy carbon, graphite, gold, silver, platinum and the like.
Body 7 is connected by wire 8 to a means capable of charging or discharging the polymer, such as power supply 11 which may be a battery or other suitable DC source, via switch 10 and variable resistor 15. The polarity of the current produced by power supply 11 may be reversed by a polarity control 16. Power supply 11 is also connected via wire 13 to counterelectrode 12. In use, electrodes 5 and 12 can be contacted with a body of physiological medium 3, such as spinal fluid, blood, lymph, fatty tissue and the like, by positioning the electrodes in or abutting the appropriate body structure 4. Except in the case of miniaturized units intended for long-term in situ drug delivery, remote powering and switching of the device is desirable. The variable resistor permits the current to be controlled. The power supply could also incorporate more sophisticated current delivery apparati, such as pulse generators, counters and recorders.
FIG. 2 illustrates in simplified form a self-contained drug delivery device suitable for implantation ina body of physiological medium 3 in a body structure 4.
The working electrode is formed from a body of charged polymer 6 which is connected by wire 8 to current supply means 21. In this device, current supply means 21 compri-ses an electrode formed of a material having sufficient 12~i6887 electrochemical potential with respect to charged polymer 6 that it will s~pply a current flow adequate to neutralize the charged sites 18 on polymeric electrode 6 when both electrodes are contacted with physiological medium 3. In this device, working electrode 6 will preferably be separated from the current-supplying electrode 21 by an insulator 20, which may be formed from a body of insulating polymer. As depicted, the current-supplying electrode 21 is negatively charged, and may be formed from a reducing agent such as a negatively charged polyacetylene or a metal such as zinc. Of course, organic or inorganic materials capable of inducing an anodic current flow could also be employed to form electrode 21. In the resting state in the devices shown in both FIGS. 1 and 2, switch 10 would be open, and the current would be off. When closed, the ano-dic or cathodic current flow initiates the delivery of the desired bioactive ions 17, which are ionically bound to the polymer to the desired concentration. As depicted, polymer 6 comprises cations 18 which ionically bind bioactive anions 17. In the implanted device shown in FIG. 2, switch 10 can be remotely activated so that the ion delivery can be initiated or interrupted without the need for surgical procedures.
The invention will be further described by reference to the following detailed examples.
Example I - Controlled Release of Glutamate Anions From Polypyrrole Films.
Polypyrrole was anodically deposited to a thickness of approximately 5 uM onto a glassy-carbon rod electrode from an aqueous solution containing sodium perch-lorate. This coated electrode, which exhibited voltam-metric properties similar to those reported by Diaz et al., cited hereinabove. The coated electrode was rinsed with water and transferred to an aqueous solution containing only sodium glutamate (0.1 M, pH=6.95). A potential/time square wave was applied between the limits of O.OV and -l.OV (SCE). At -l.OV the film was reduced; at O.OV, it was reoxidized. The cyclic voltammogram of the coated electrode was altered by this procedure, and could be restored to its original shape in a perchlorate solution.
The glutamate-loaded electrode was transferred to an aqueous sodium chloride solution where a 2.0 minute cathodic pulse (-l.OV) was effective to release glutamate anions. The electrode was then reloaded, washed and gluta-mate again released into the same solution. Amino acid analysis showed that 2.7x10-3 mol cm~2 of electrode area of glutamate anions had been released. This is about 200 times the amount released by the reductive release of covalently-bound glutamic acid as described hereinabove.
In a control experiment, the loaded electrode was prepared and exposed to aqueous NaCl in the absence of current passage. Only 1.9xlO-9 mol cm~2 of glutamate was released.
Example II - FerricYanide Release from Polypyrrole Films.
To study ferricyanide anion (FCN) release from polypyrrole films, the films were deposited from aqueous 0.05 M sodium chloride solutions that were 0.05 M in pyrrole and 0.01-0.03 M in FCN, by anodic oxidation at 0.7 V onto glassy carbon electrodes. The coated electrode was transferred to an aqueous solution containing only the NaCl electrolyte and a typical cyclic voltammogram (film thickness=l uM) is shown in FIG. 3. Well defined waves for the FCN redox couple (solid curve) are superimposed on the large polypyrrole (PP) background. Integration of the peak current gave an estimated value for the amount of electroactive FCN in the polymer as 3.2x10-3 mol cm~2. The i266887 /
FCN redox waves were stable to cycling within potential range of -0.3 to +0.4 V, and after 17 hr in buffered pH 7 solution the peak current mai~tained 94% of its initial height. Stepping the potential for ca. 2 min to -1.0 V
caused a dramatic change in the voltammetric response of the film. The redox couple of FCN at about 0.1 V disap-peared (FIG. 3 dashed line) indicating the release of FCN
anions during the reduction of the film.
The crucial experiments involved measuring the amount of FCN released and demonstrating that the amounts released could be completely controlled. A four electrode small volume ~droplet) cell was constructed employing a ring (Pt)-disc (GC) electrode. The cell structure was otherwise as described in Neurosci. Letters, 35, 101 (1983).
The disc had been previously coated with PP/FCN film. A constant potential pulse (-0.8V vs Ag/AgCl) was applied to the disc for 2 min. The ring was then made the working electrode, and by cycling the potential of the ring from -0.1 to +0.6 V, FCN was released as desired. In a control experiment the cell was assembled as usual, but no current was passed. No FCN was found in solution.
Hence the release of FCN is triggered by the reduction of the film. No evidence for a spontaneous ion exchange bet-ween FCN in the film and other anions in the solution wasfound.
In further experiments, the amount of FCN
released was quantitated in various film thickness. The results shown in Table-I indicate that the amount of released material was proportional to the thickness of the film, when the thickness was less than 1 uM.
Table I. Yield of FCN released from GC/PP/FCN Polymera Film Thicknessb(uM) Yield (nmol cm~2)C Conc(mM)d .
0.11 2.58 0.024 0.53 10.2 0.094 0.52 10.5 0.096 1.05 20.3 0.173e 0.98 19.8 0.182 3.31 38.1 0.,35 3.36 46.5 0.43 a The disc was pulsed for 2 min at -0.8 V (vs. Ag/AgCl 3M
KCl). The volume of the electrolyte droplet was 50 uL.
b The thickness was estimated taking 24 mC cm~2 equivalent to 0.1 um.
c Surface concentration of the FCN.
d Solution concentration of FCN after release.
e The volume of electrolyte droplet was 70 uL.
It was also of interest to apply short pulses to GC/PP/FCN
and to check the amount of the released material to demonstrate quantitative control. Using the small volume cell (50uL, O.lM NaCl) the coated disc was pulsed for 1 sec (at -0.8 V). After each pulse a cyclic voltammogram (CV) using the ring was taken. In this way the profile of FCN
concentration as a function of time was obtained. The results are shown in FIG. 4. The peak current from released FCN is plotted vs the number of pulses for dif-ferent thickness of films. The amount of the released FCN
increased to a constant value after about twelve pulses and the total amount of the released FCN after these twelve one-second pulses was in agreement with the amount found previously for a 2 min. pulse.
The results of Examples I and II clearly ~2668a7 demonstrate that a polymeric film can be electrically controlled to intermittently release controlled amounts of the ionically-bound counteranions.
Example III - Controlled Release of Glutamate Anions from Polymerized 3-Methoxythiophene.
A cyclic voltammogram (CV) of 1.34 mM
3-methoxythiophene in H2O-CH3CN l3:1) containing 0.01 M
NaClO4 at a glassy carbon disk (A = 0.090 cm2) at a scan rate of 100 mVs~l exhibits an irreversible wave at +1.32 V
(SCE). Constant potential oxidation of a 35.0 mM solution of 3-methoxythiophene at +1.30V (SCE) in the same electro-lyte for 10 sec. (Q = 7.21 mC) resulted in the formation of a film on the electrode surface. This coated electrode was removed from the coating solution, dipped several times in water, and introduced into an aqueous 0.01 M NaClO4 solu-tion. After 5-10 cycles between +0.80 and -0.50 V, repro-ducible steady-state cyclic voltammograms were recorded.
As is the case with polythiophene and several of its deri-vatives, one oxidative wave and two rather broad reduction waves are observed, albeit at potentials nearly 700 mV less positive than those for polythiophene. As the scan rate was increased from 20 to 200 mVs~l, the peak potential for the oxidative wave (Epa) increased from 310 to 420 mV, the peak current divided by the scan rate decreased from 2.375 to 1.568 uAs(mV)~l, and the charge of the oxidative peak decreased from 0.529 to 0.472 mC.
Films of polymerized 3-methoxythiophene with varying thicknesses were prepared by varying the oxidation - time. Both the oxidized and reduced states of polymerized 3-methoxythiophene are quite stable in the presence of oxy-gen and water. CVs of either film in aqueous C104- are virtually identical before and after exposure to air for periods of 6-12 hr or after repeated cycling between ~0.80 ~266887 and -0.50 V. After 40 cycles in this potential range, only a 5% decrease in Q was observed. Surprisingly, it was found that the reduced film of polymerized 3-methoxythiophene, which is green in reflected light, is quite soluble in CH3CN, CH2C12, acetone and DMF, forming deep red solutions. The oxidized form, which appears gold in reflected light, is not very soluble in CH3CN, CH2C12, and acetone, but can be dissolved in DMF giving a deep blue solution.
The appreciable solubility of polymerized 3-methoxythiophene provides for the first time an alternate method for preparing films of this material. The processa-bility of the polymer was demonstrated by dissolving the reduced film in CH2C12 and coating a glassy carbon electrode with the polymer by evaporation of the solvent.
The electrochemical response of the coated polymer was essentially identical to that achieved before dissolution.
CVs of films with varying thicknesses prepared in this manner were recorded in 2:1 H2O-CH3CN containing 0.01 M
NaClO4. From the Q of the oxidative wave taken with the assumption that the film is poly(3-methoxythiophene), the percentage of thiophene units in the film that are charged (e.g., level of doping) was calculated. The percentage decreased from 15 to 9 as the ug of polymer per cm2 is increased from 21.6 to 140. A doping level of 25~ has been reported for polyt3-methylthiophene) based upon elemental analysis by G. Tourillon et al., in J. Electroanal. Chem., 161, 51 (1984).
Polymerized 3-methoxythiophene was successfully employed as a vehicle for delivery of negatively charged drugs. The CV indicates that ~26688`7 the polymer can be doped with the neurotransmitter gluta-mate as the counterion, but at a lower level than with perchlorate.
To demonstrate that polymerized 3-methoxythiophene can load and unload glutamate by electrochemical pulsing, a glassy carbon rod with a surface area of 10,8 cm2 was coated with the oxidized film to a capacity of 463 mC cm~2. The coated electrode was dipped in water and transferred to an aqueous O.lQ M glutamate solution where sequential potentials of -0.50, +0.80, -0.50, and +0.80 V were applied, each for 30 sec. This pulsing procedure replaces (at least in part) perchlorate in the film with glutamate. The oxidized electrode was removed, dipped in water, and washed by dipping in an aqueous solution of 0.10 M NaClO4 (Solution A) for two minutes. The coated electrode was transferred to a second aqueous solution of 0.10 M NaClO4 (Solution B) for another two-minute period. For the electrochemical unloading of glutamate, the coated electrode was transferred to a third aqueous 0.10 M NaClO4 solution (Solution C) which occupied the center compartment of a three-compartment cell. The compartments each contained 0.10 M NaClO4 and were separated by a glass frit and an aqueous agar (0.50 M
NaClO4). A carbon sponge served as the counter electrode in the second compartment and the SCE reference electrode occupied the third compartment.
The potential of the coated electrode was pulsed at -0.50 V and back to +0.80 V as in the glutamate solu-tion. The electrode was dipped in water and returned to the glutamate solution for reloading. This loading-unloading procedure was carried out a total of four times.
Then, using an amino acid analyzer, solutions A, B, and C
were found to contain 101, 12, ar.d 224 ug of sodium gluta-mate, respectively. The data show that some glutamate is weakly bound and easily washed from the film. A larger quantity, however, is more strongly bound, and is only released by reduction of the film. Thus, polymerized 3-methoxythiophene can be used to deliver glutamate and the coated electrode can be readily reloaded. Furthermore, taking into account differences in electrode surface area, the average amount of glutamate released in each loading-unloading sequence was nearly 200 times greater than the amount of glutamate that was released from polystyrene polymers containing covalently bound glutamic acid.
This example indicates that polymerized 3-methoxythiophene satisfies the criteria for a useful drug delivery material. Furthermore, its solubility makes this material processable, in that coatings of the polymer can be applied to conductive substrates by applying solutions thereof and evaporating the carrier solvent.
It is expected that a wide variety conductive polymers can be prepared and employed for the controlled release of ionic organic pharmaceuticals of varying struc-ture using techniques such as those set forth in the pre-sent Examples.
Although the invention has been described withreference to various specific and preferred embodiments and techniques, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
DRUG DELIVERY SYSTEM
U.S.P.H.S. and N.S.F. Support This invention was made with Government support under Contract Number 5-R01-GM-24493, awarded by the U.S.
Public Health Service and Contract Number CHE-8203493, awarded by the National Science Foundation. The Government has certain rights in the invention.
Background of the Invention The controlled release of bioactive substances such as drugs has become an important mode of treatment for many diseases and disorders. Pharmaceutical manufacturers have introduced many products which are designed to gra-dually release bioactive substances at a therapeutically-useful rate and to spatially target the release. For example, the release rate may be controlled mechanically by a valving system, or physically, as by slow drug diffusion through protective encapsulation.
Iontophoresis is an electrochemical process which has found limited utility for the controlled application of charged agents such as metal ions, analgesics and anesthe-tics to afflicted bodily areas such as infla~ed joints.
Iontophoresis utilizes direct electrical current to drive ionized chemicals through the intact skin. For example, in aqueous media, sodium salicylate disassociates into ions.
The salicylate ions responsible for the analgesic action of the salt are negatively charged. Accordingly, these active species can be driven through the skin by the repelling action of a cathodic current which is applied to a reser-voir containing the active species. Thus, when ion-. ~
~26S887 tophoresing salicylate through the skin, the electrodecontacting the salicylate solution must be connected to the positive pole of a battery while the counter-electrode which contacts the skin at some remote point is connected to the negative pole to provide a return path for the current. Simple circuits effective to conduct ion-tophoresis are disclosed in U.S. Pat. No. 3,991,755.
However, special difficulties are encountered in therapeutic or experimental situations where it is desired to release discrete units of highly active agents in vivo.
For example, in neuroscience, it is important to be able to deliver neurotransmitters or drugs to specific locations at specific times. In this way, the effect of these com-pounds on single neurons can be studied. Iontophoresis hasbeen employed for drug delivery at the single neuron level, whereby a solution of an active electrolyte is placed in a micropipet and then "phoresed" out with a small current.
Although widely used, this technique suffers from a number of disadvantages, primarily related to quantification control. It is also necessary to apply the active substance in combination with a relatively large quantity of a carrier liquid to the area to be treated or tested.
One electrochemical alternative to iontophoresis is presented by L. L. Miller et al. in Neuroscience Letters, 35, 101 (1983? and J. Amer. Chem. Soc., 105, 5271, 5278 ~1983), who disclose electrodes which are used to deliver the neutral neurotransmitters dopamine (3, 4-dihydroxy-phenethylamine), glutamic acid and gamma-amino-butyric acid from their surfaces in response to an electri-cal signal. A compound electrode was constructed by coating an inert electrode with a polystyrene-based polymer film having the neurotransmitter covalently bound to the polymer backbone through an amide linkage. At sufficiently negative potentials, cathodic reduction cleaved the amide ~.2~8fl7 --3~
bond and released the neurotransmitter into a small volume of aqueous buffer. The released amine was detected at a second electrode by its electrochemical oxidation or alter-natively, analyzed by HPLC. Although this method permitted the release of a bioactive agent into a physiological medium, the amounts released at neutral pH were very low, and could not be appreciably increased by increasing the amount of loaded polymer on the electrode, due to slow charge propagation within the film.
The use of such polymers for drug delivery is disadvantageous, since a separate chemical synthesis is required to incorporate the active species into the polymer. Furthermore, polymers bearing covalently-bound drugs cannot be easily reloaded once the drug has been released from the polymeric matrix. Therefore, a need exists for a electrochemical method for the controlled delivery of charged bioactive chemical species from an electrode into physiological media such as blood, lymph, spinal fluid and the like.
8rief Description of the Invention The present invention is directed to controlled release drug delivery systems which employ an electrode comprising a polymer which can be electrochemically cycled between the charged and the neutral, or insulating states.
In the charged, or ionic state, the polymer can be loaded with bioactive counterions. When the charge on the polymer is neutralized or reversed, the counterions are released into the surrounding medium and become available to perform their intended function, e.g. to exert their phar-macological activity.
In practice, a body of the conductive polymer can be employed to form the active portion of a working electrode. The polymer is then charged cathodically or anodically while in contact with an aqueous medium con-i266a87 taining the desired drug counterion causing it toionically-bind a pharmaceutically-effective amount of the counterions. The drug-loaded electrode is then contacted with a physiological medium. As used herein, the term phy-siological medium is intended to refer to an electrolyticsolution which is either a naturally-occurring body fluid such as blood, lympht cerebrospinal fluid or the like, or which is formulated to approximate the properties of such fluids. For example, the electrode may be implanted in a natural or artifically-formed body cavity or placed in con-tact with the skin, mucous membranes or the like. The drug counterions can then be released in vivo in a controlled fashion by one or more quantified current pulses.
For example, these polymers can be loaded with anionic compounds which are bioactive, such as amino acids, by converting the polymer into the oxidized or electroposi-tive state with an anodic current in the presence of dissolved amino acid carboxylate salts. once loaded, one or more cathodic pulses can be employed to electrically neutralize the polymer, resulting in the release of all or a part of the bioactive counteranions into the desired medium. The polymer can be removed from the delivery locale, reloaded and reused if desired. The unit dosage of the bioactive compound can be controlled by adjusting para-meters such as the release pulse strength and duration, theloading concentration and the electrode conformation and position.
1266a87 -4a-BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a simplified illustration of one embodiment of a drug delivery system of the present invention.
Fig. 2 is a simplified illustration of an embodiment of a self-contained drug system of the present invention.
Fig. 3 depicts cyclic voltammograms recorded for an electrode comprising a conductive polypyrrole film, with and without bound ferricyanide.
Fig. 4 is a graphic depiction of the profile of ferri-cyanide release from an electrode comprising a conductivepolypyrrole film.
Detailed Description of the Invention Pre~aration and Loadin~ of Electroactive Polvmers Polymers useful in the present invention are ~hose organic or organometallic polymers which (a) comprise functional groups which can be electroclemically cycled between the charged and neutral states and (b) possess the , .
:. ', :
~266887 physical proper~ies required for use as working electrodes.
These polymers are preferably stable in air and water, highly conductive and processable.
In the charged state, these polymers can attract and retain oppositely-charged, pharmaceutically-effective amounts of bioactive chemical species. The ionically-bound species can be released from the polymeric matrix when the polymeric charge is neutralized. For example, polymers which comprisè cationic sites in the charged state can be loaded with bioactive anions which are delivered by employing a cathodic current to neutralize the positively charged polymer, while polymers which comprise anionic sites when charged can be used to bind and release active species which are cationic.
Such charged polymers may be considered as belonging to two broad classes: (a) those comprising redox sites which are covalently bound to an electrically inac-tive backbone, such as poly(vinylferrocene); and (b) those having redox sites integrally-incorporated into the poly-meric backbone. The latter type will be referred to herein - as "conductive polymers". For a general discussion of t these two classes of charged polymers, see L. R. Faulkner, Chem. Eng. News (Feb. 27, 1984) at pages 31-35.
Conductive polymers can be switched from the charged (conductive) and nonconducting (neutral) states by employing an electric current to alternately reduce and oxidize the polymer chain. Although the redox sites on polymers of type (a) can also be electrochemically oxidized and reduced, these polymers cannot readily pass current by - electron transfer along the back-bone. Conductive polymers, on the other hand, permit direct electron transfer along the polymeric chains, pre-ferably vla a pi-electron network. When such polymers are electrically neutral, the bonding states in the pi-electron ., .~
~, ~
,,t.~
~2668~7 network are full and electronic conductivity is very low.
The removal of pi-electrons creates cationic vacancies that permit current to ~low along the chains, while addition of pi-electrons to vacancies in neutral systems can produce anionic sites.
Since these polymers are essentially metallic in character, they can be designed to bear high charge den-sities and exhibit efficient charge transfer. Furthermore, they need not be bound to a conductive electrode surface in order for the redox sites to be charged and discharged, but can be formed into free-standing bodies which can function as working electrodes when connected to a current source.
Cationic charged polymers such as those comprising unsaturated carbocyclic or heterocyclic rings such as phenyl, pyrrole, pyridyl, cyclopentadienyl and thiafulvalenyl can be used in the invention. Preferably the rings will be linked into a continuous conjugated, pi-electron network, such as those present in polyaromatic or poly-(pseudo-aromatic) systems. One preferred class of conductive polymer is the polypyrroles, which are formed by the electrochemical oxidation of a pyrrole as described by A. F. Diaz et al. in J. Chem. Soc. Chem. Commun., 635, 854 (1979).
Polythiophene and several beta-substituted polythiophenes have been prepared by electrochemical oxida-tion and polymerization of their respective monomers.
These polymers can be repeatedly cycled between a conduc-tive oxidized state and a semi-conductive neutral state.
See G. Tourillon, J. Electroanal. Chem., 161, 51 (1984).
Although their stability in aqueous media indicates that these polymers might be useful to deliver anionic drugs, their high oxidation potentials (greater than 0.70V vs.
SCE) would eliminate the delivery of drugs that are electroactive in this potential region. The beta-substituted-thiophene, poly-3-methoxythiophene was prepared i26~;a87 and found to possess a significantly lower oxidation poten-tion. This material can be employed to deliver anions such as amino acid carboxylates according to the method of this invention.
Other conductive polymers useful to bind and release anions include substituted poly(pyrroles), substi-tuted polythiophenes and similar poly(heterocyclic) materials. Other useful conductive polymers include polyanilines, poly(thiophenols), poly(aromatics) or polyacetylenes. For example, see Chem Eng. News (Sept. 10, 1984) at pages 38-39. Conductive polymers useful for the delivery of cations can also come from the classes of polyacetylenes as well as polyaromatics or poly(heteroaromatics). For example, poly(9-phenylquino-line) would be charged negatively to hold cations, thendischarged.
Redox polymers of the type (a) which can be used to deliver bioactive anionic species include polymers holding a variety of cationic metal complexes either electrostatically or covalently. Examples include organic polymers with pendant ligands such as cyclopentadienyl, pyridine, bipyridine, tripyridine, primary amines, porphyrins, phthalocyanines and related macrocyclic ligands. These ligands can bind a wide variety of metal ions including iron, cobalt, ruthenium, osmium which are capable of rapid electron transfer reactions between the redox centers. Organic polymers which could be used as anion delivery agents include those with pendant groups that are relatively stable in both the oxidized and reduced forms, like tetrathiofulvalene, aromatic diamines, cationic dyes such as those from the classes thiazines, diazines, oxazines, triarylmethanes, cyanines, mercocyanines and the like. Polymers of type (a) useful for cation delivery include metal complexes with a net negative charge like sulfonated complexes or oxyanions like the conjugate anion ~z66a~37 of a hydroquinone or an enolate. Carboxylated or sulfo-nated aromatics could also be useful, especially when the aromatic moiety is substituted by nitro, carbonyl, or sulfonyl. Anionic dyes of interest may be selected from anionic cyanines, oxonoles, quinones, and the like.
The charged polymers can be employed to form working electrodes by electrochemically oxidizing or reducing a solution of appropriate monomer so as to deposit a coating of the charged polymer on the surface of a con-ventional electrode. If the monomer can be polymerized inthe presence of the desired counterion, it will be depo-sited in the loaded condition. If the monomer will not polymerize electrochemically in the presence of the desired counterion, the undesired counterion may be exchanged for the desired species by cycling the polymeric electrode bet-ween the neutral and charged state in contact with a medium containing an excess of the desired counterions. In this manner, the undesired ions are forced out and replaced with the desired ions.
Working electrodes comprising the present charged polymers can be formed in a wide variety of sizes, from microelectrodes of about 1 uM2 to electrodes designed to encompass an inflamed joint or to cover a large area of a patient's skin. In many cases it will be desirable to coat inert substrates of high surface area with the chargedpolymer, in order to increase the reservoir of the active species bound thereto. Implantable electrodes, or those designed for parenteral drug delivery can be fabricated from polymer coated screens or mesh, or could consist essentially of appropriately-shaped bodies of the conduc-tive polymeric material. The screens or mesh may be com-posed of a wide variety of conducting materials including metals or carbon fibers.
Especially preferred polymers for use in the pre-sent invention are those which are soluble in organic ~266aa7 solvents in either the charged or neutral state. Thesepolymeric solutions can be used to form films of controlled thickness by applying coatings of the solutions to ccnduc-tive electrode substrates, as by dip- or spin coating and then evaporating the carrier solvent. For example, the reduced form of poly-3~methoxythiophene is soluble in ace-tonitrile, methylene chloride, acetone and dimethyl for-mamide (DMF) while the oxidized form is soluble in DMF.
Bioactive Counterions The present drug-delivery method is generally applicable to the release of ionic materials such as orga-nic cations and anions. Anionic bioactive species useful as counterions include the pharmaceutically-acceptable salts of carboxylates, phosphates, sulfates, bisulfites, and the salts of acidic N-H moieties such as amides. Many useful drugs containing these functional groups are commer-cially available as their water-soluble alkali metal or alkaline earth metal salts, most commonly as sodium, lithium, potassium, magnesium or calcium salts.
Useful bioactive organic carboxylate salts - include sodium ethacrynate, levothyroxine sodium, valproate sodium, magnesium salicylate, clorazepate sodium, sodium folate, leucovorin calcium, sodium ascorbate, cephaprin sodium, cephalothin sodium, penicillin G potassium, dextrothyroxine sodium and the carboxylate salts of amino acids. Many carboxylic acid-containing drugs can be con-verted into pharmaceutically-acceptable water-soluble salts by conventional techniques, including aspirin, prostaglan-dins, retinoic acid, furosemide, tricrynafen, probenicidand the like.
Also useful as anionic counterions are phosphate salts such as cortisol sodium phosphate, menadiol sodium phosphate, etidronate disodium phosphate, triclofos sodium and the like; sulfates such as estrone potassium sulfate ~z668a7 and heparin sodium; bisulfates such as menadione sodium bisulfite and the salts of acidic amines such as purines and amides, including sulfacetamide sodium, tolbutamide sodium, sulfadiazine sodium and the salts of aminophylline, theophylline and the like.
Bioactive cationic species include the pharmaceutically-acceptable salts such as the halide, nitrate and methylsulfate salts of quaternary amines and charged sulfur and nitrogen-containing heterocyclic drugs, such as those comprising thiazinium, pyridinium, pyrrolidi-nium, thiazolium or piperidinium salts. Drugs comprising quaternary amines include gallamine triethiodide, meto-curine iodide, hexafluorenium bromide, decamethonium bro-mide, pancuronium bromide, succinyl choline chloride, neostigmine bromide, demacarcium bromide, amberonium chloride, diphemanil methyl sulfate, choline chloride, and the like. Useful heterocyclic salts include thiamine nitrate, methylene blue, trimethaphan camsylate, cetylpyri-dinium chloride and pyridostigmine bromide.
Neutral, pharmacologically-active species may also be loaded and released via the electroactive polymers if they are first modified to introduce suitable ionic functional groups, such as the above-mentioned phosphates, sulfates, quaternarized nitrogen and the like. Techniques for introducing such polar groups are well-known and widely-employed to increase the water-solubility of drugs which are nonsoluble or only sparingly soluble in water, so that they may be orally administered. Such techniques include the conversion of hydroxyl groups to halides and then to phosphonoxy or phosphinoxy groups, and the conver-sion of hydroxyl groups to the salts of half esters.
Bisulfites may be formed by the conjugate addition of bisulfite salts to alpha, beta-unsaturated ketones, and amines may be quaternized with alkyl halides.
Controlled Dru~ Release Systems Devices useful for the controlled delivery of bioactive ions into physiological media such as mammalian fluids or tissues, are schematically depicted in FIGS . 1 and 2.
In the simplified form illustrated in FIG. 1, the drug delivery device incorporates working electrode S
which, as illustrated, comprises a coating of the charged polymer 6 on an inert conductive body 7. Body 7 may be formed of any physiologically inert substance, e.g. glassy carbon, graphite, gold, silver, platinum and the like.
Body 7 is connected by wire 8 to a means capable of charging or discharging the polymer, such as power supply 11 which may be a battery or other suitable DC source, via switch 10 and variable resistor 15. The polarity of the current produced by power supply 11 may be reversed by a polarity control 16. Power supply 11 is also connected via wire 13 to counterelectrode 12. In use, electrodes 5 and 12 can be contacted with a body of physiological medium 3, such as spinal fluid, blood, lymph, fatty tissue and the like, by positioning the electrodes in or abutting the appropriate body structure 4. Except in the case of miniaturized units intended for long-term in situ drug delivery, remote powering and switching of the device is desirable. The variable resistor permits the current to be controlled. The power supply could also incorporate more sophisticated current delivery apparati, such as pulse generators, counters and recorders.
FIG. 2 illustrates in simplified form a self-contained drug delivery device suitable for implantation ina body of physiological medium 3 in a body structure 4.
The working electrode is formed from a body of charged polymer 6 which is connected by wire 8 to current supply means 21. In this device, current supply means 21 compri-ses an electrode formed of a material having sufficient 12~i6887 electrochemical potential with respect to charged polymer 6 that it will s~pply a current flow adequate to neutralize the charged sites 18 on polymeric electrode 6 when both electrodes are contacted with physiological medium 3. In this device, working electrode 6 will preferably be separated from the current-supplying electrode 21 by an insulator 20, which may be formed from a body of insulating polymer. As depicted, the current-supplying electrode 21 is negatively charged, and may be formed from a reducing agent such as a negatively charged polyacetylene or a metal such as zinc. Of course, organic or inorganic materials capable of inducing an anodic current flow could also be employed to form electrode 21. In the resting state in the devices shown in both FIGS. 1 and 2, switch 10 would be open, and the current would be off. When closed, the ano-dic or cathodic current flow initiates the delivery of the desired bioactive ions 17, which are ionically bound to the polymer to the desired concentration. As depicted, polymer 6 comprises cations 18 which ionically bind bioactive anions 17. In the implanted device shown in FIG. 2, switch 10 can be remotely activated so that the ion delivery can be initiated or interrupted without the need for surgical procedures.
The invention will be further described by reference to the following detailed examples.
Example I - Controlled Release of Glutamate Anions From Polypyrrole Films.
Polypyrrole was anodically deposited to a thickness of approximately 5 uM onto a glassy-carbon rod electrode from an aqueous solution containing sodium perch-lorate. This coated electrode, which exhibited voltam-metric properties similar to those reported by Diaz et al., cited hereinabove. The coated electrode was rinsed with water and transferred to an aqueous solution containing only sodium glutamate (0.1 M, pH=6.95). A potential/time square wave was applied between the limits of O.OV and -l.OV (SCE). At -l.OV the film was reduced; at O.OV, it was reoxidized. The cyclic voltammogram of the coated electrode was altered by this procedure, and could be restored to its original shape in a perchlorate solution.
The glutamate-loaded electrode was transferred to an aqueous sodium chloride solution where a 2.0 minute cathodic pulse (-l.OV) was effective to release glutamate anions. The electrode was then reloaded, washed and gluta-mate again released into the same solution. Amino acid analysis showed that 2.7x10-3 mol cm~2 of electrode area of glutamate anions had been released. This is about 200 times the amount released by the reductive release of covalently-bound glutamic acid as described hereinabove.
In a control experiment, the loaded electrode was prepared and exposed to aqueous NaCl in the absence of current passage. Only 1.9xlO-9 mol cm~2 of glutamate was released.
Example II - FerricYanide Release from Polypyrrole Films.
To study ferricyanide anion (FCN) release from polypyrrole films, the films were deposited from aqueous 0.05 M sodium chloride solutions that were 0.05 M in pyrrole and 0.01-0.03 M in FCN, by anodic oxidation at 0.7 V onto glassy carbon electrodes. The coated electrode was transferred to an aqueous solution containing only the NaCl electrolyte and a typical cyclic voltammogram (film thickness=l uM) is shown in FIG. 3. Well defined waves for the FCN redox couple (solid curve) are superimposed on the large polypyrrole (PP) background. Integration of the peak current gave an estimated value for the amount of electroactive FCN in the polymer as 3.2x10-3 mol cm~2. The i266887 /
FCN redox waves were stable to cycling within potential range of -0.3 to +0.4 V, and after 17 hr in buffered pH 7 solution the peak current mai~tained 94% of its initial height. Stepping the potential for ca. 2 min to -1.0 V
caused a dramatic change in the voltammetric response of the film. The redox couple of FCN at about 0.1 V disap-peared (FIG. 3 dashed line) indicating the release of FCN
anions during the reduction of the film.
The crucial experiments involved measuring the amount of FCN released and demonstrating that the amounts released could be completely controlled. A four electrode small volume ~droplet) cell was constructed employing a ring (Pt)-disc (GC) electrode. The cell structure was otherwise as described in Neurosci. Letters, 35, 101 (1983).
The disc had been previously coated with PP/FCN film. A constant potential pulse (-0.8V vs Ag/AgCl) was applied to the disc for 2 min. The ring was then made the working electrode, and by cycling the potential of the ring from -0.1 to +0.6 V, FCN was released as desired. In a control experiment the cell was assembled as usual, but no current was passed. No FCN was found in solution.
Hence the release of FCN is triggered by the reduction of the film. No evidence for a spontaneous ion exchange bet-ween FCN in the film and other anions in the solution wasfound.
In further experiments, the amount of FCN
released was quantitated in various film thickness. The results shown in Table-I indicate that the amount of released material was proportional to the thickness of the film, when the thickness was less than 1 uM.
Table I. Yield of FCN released from GC/PP/FCN Polymera Film Thicknessb(uM) Yield (nmol cm~2)C Conc(mM)d .
0.11 2.58 0.024 0.53 10.2 0.094 0.52 10.5 0.096 1.05 20.3 0.173e 0.98 19.8 0.182 3.31 38.1 0.,35 3.36 46.5 0.43 a The disc was pulsed for 2 min at -0.8 V (vs. Ag/AgCl 3M
KCl). The volume of the electrolyte droplet was 50 uL.
b The thickness was estimated taking 24 mC cm~2 equivalent to 0.1 um.
c Surface concentration of the FCN.
d Solution concentration of FCN after release.
e The volume of electrolyte droplet was 70 uL.
It was also of interest to apply short pulses to GC/PP/FCN
and to check the amount of the released material to demonstrate quantitative control. Using the small volume cell (50uL, O.lM NaCl) the coated disc was pulsed for 1 sec (at -0.8 V). After each pulse a cyclic voltammogram (CV) using the ring was taken. In this way the profile of FCN
concentration as a function of time was obtained. The results are shown in FIG. 4. The peak current from released FCN is plotted vs the number of pulses for dif-ferent thickness of films. The amount of the released FCN
increased to a constant value after about twelve pulses and the total amount of the released FCN after these twelve one-second pulses was in agreement with the amount found previously for a 2 min. pulse.
The results of Examples I and II clearly ~2668a7 demonstrate that a polymeric film can be electrically controlled to intermittently release controlled amounts of the ionically-bound counteranions.
Example III - Controlled Release of Glutamate Anions from Polymerized 3-Methoxythiophene.
A cyclic voltammogram (CV) of 1.34 mM
3-methoxythiophene in H2O-CH3CN l3:1) containing 0.01 M
NaClO4 at a glassy carbon disk (A = 0.090 cm2) at a scan rate of 100 mVs~l exhibits an irreversible wave at +1.32 V
(SCE). Constant potential oxidation of a 35.0 mM solution of 3-methoxythiophene at +1.30V (SCE) in the same electro-lyte for 10 sec. (Q = 7.21 mC) resulted in the formation of a film on the electrode surface. This coated electrode was removed from the coating solution, dipped several times in water, and introduced into an aqueous 0.01 M NaClO4 solu-tion. After 5-10 cycles between +0.80 and -0.50 V, repro-ducible steady-state cyclic voltammograms were recorded.
As is the case with polythiophene and several of its deri-vatives, one oxidative wave and two rather broad reduction waves are observed, albeit at potentials nearly 700 mV less positive than those for polythiophene. As the scan rate was increased from 20 to 200 mVs~l, the peak potential for the oxidative wave (Epa) increased from 310 to 420 mV, the peak current divided by the scan rate decreased from 2.375 to 1.568 uAs(mV)~l, and the charge of the oxidative peak decreased from 0.529 to 0.472 mC.
Films of polymerized 3-methoxythiophene with varying thicknesses were prepared by varying the oxidation - time. Both the oxidized and reduced states of polymerized 3-methoxythiophene are quite stable in the presence of oxy-gen and water. CVs of either film in aqueous C104- are virtually identical before and after exposure to air for periods of 6-12 hr or after repeated cycling between ~0.80 ~266887 and -0.50 V. After 40 cycles in this potential range, only a 5% decrease in Q was observed. Surprisingly, it was found that the reduced film of polymerized 3-methoxythiophene, which is green in reflected light, is quite soluble in CH3CN, CH2C12, acetone and DMF, forming deep red solutions. The oxidized form, which appears gold in reflected light, is not very soluble in CH3CN, CH2C12, and acetone, but can be dissolved in DMF giving a deep blue solution.
The appreciable solubility of polymerized 3-methoxythiophene provides for the first time an alternate method for preparing films of this material. The processa-bility of the polymer was demonstrated by dissolving the reduced film in CH2C12 and coating a glassy carbon electrode with the polymer by evaporation of the solvent.
The electrochemical response of the coated polymer was essentially identical to that achieved before dissolution.
CVs of films with varying thicknesses prepared in this manner were recorded in 2:1 H2O-CH3CN containing 0.01 M
NaClO4. From the Q of the oxidative wave taken with the assumption that the film is poly(3-methoxythiophene), the percentage of thiophene units in the film that are charged (e.g., level of doping) was calculated. The percentage decreased from 15 to 9 as the ug of polymer per cm2 is increased from 21.6 to 140. A doping level of 25~ has been reported for polyt3-methylthiophene) based upon elemental analysis by G. Tourillon et al., in J. Electroanal. Chem., 161, 51 (1984).
Polymerized 3-methoxythiophene was successfully employed as a vehicle for delivery of negatively charged drugs. The CV indicates that ~26688`7 the polymer can be doped with the neurotransmitter gluta-mate as the counterion, but at a lower level than with perchlorate.
To demonstrate that polymerized 3-methoxythiophene can load and unload glutamate by electrochemical pulsing, a glassy carbon rod with a surface area of 10,8 cm2 was coated with the oxidized film to a capacity of 463 mC cm~2. The coated electrode was dipped in water and transferred to an aqueous O.lQ M glutamate solution where sequential potentials of -0.50, +0.80, -0.50, and +0.80 V were applied, each for 30 sec. This pulsing procedure replaces (at least in part) perchlorate in the film with glutamate. The oxidized electrode was removed, dipped in water, and washed by dipping in an aqueous solution of 0.10 M NaClO4 (Solution A) for two minutes. The coated electrode was transferred to a second aqueous solution of 0.10 M NaClO4 (Solution B) for another two-minute period. For the electrochemical unloading of glutamate, the coated electrode was transferred to a third aqueous 0.10 M NaClO4 solution (Solution C) which occupied the center compartment of a three-compartment cell. The compartments each contained 0.10 M NaClO4 and were separated by a glass frit and an aqueous agar (0.50 M
NaClO4). A carbon sponge served as the counter electrode in the second compartment and the SCE reference electrode occupied the third compartment.
The potential of the coated electrode was pulsed at -0.50 V and back to +0.80 V as in the glutamate solu-tion. The electrode was dipped in water and returned to the glutamate solution for reloading. This loading-unloading procedure was carried out a total of four times.
Then, using an amino acid analyzer, solutions A, B, and C
were found to contain 101, 12, ar.d 224 ug of sodium gluta-mate, respectively. The data show that some glutamate is weakly bound and easily washed from the film. A larger quantity, however, is more strongly bound, and is only released by reduction of the film. Thus, polymerized 3-methoxythiophene can be used to deliver glutamate and the coated electrode can be readily reloaded. Furthermore, taking into account differences in electrode surface area, the average amount of glutamate released in each loading-unloading sequence was nearly 200 times greater than the amount of glutamate that was released from polystyrene polymers containing covalently bound glutamic acid.
This example indicates that polymerized 3-methoxythiophene satisfies the criteria for a useful drug delivery material. Furthermore, its solubility makes this material processable, in that coatings of the polymer can be applied to conductive substrates by applying solutions thereof and evaporating the carrier solvent.
It is expected that a wide variety conductive polymers can be prepared and employed for the controlled release of ionic organic pharmaceuticals of varying struc-ture using techniques such as those set forth in the pre-sent Examples.
Although the invention has been described withreference to various specific and preferred embodiments and techniques, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention.
Claims (6)
1. A system for the controlled release of a bioactive ionic chemical into a physiological medium comprising:
(a) a working electrode comprising a charged conductive polymer;
(b) a bioactive ionic chemical ionically bound to said electrode; and (c) means comprising a power supply of reversible polarity which is capable of charging or discharging said polymer by delivering an anodic or cathodic current thereto.
(a) a working electrode comprising a charged conductive polymer;
(b) a bioactive ionic chemical ionically bound to said electrode; and (c) means comprising a power supply of reversible polarity which is capable of charging or discharging said polymer by delivering an anodic or cathodic current thereto.
2. The system of claim 1 wherein said electrode comprises a coating of said conductive polymer on an inert, conductive substrate.
3. The system of claim 1 wherein the electrode consists essentially of said conductive polymer.
4. The system of claim 1 wherein said polymer comprises a continuous, conjugated pi-electron network.
5. The system of claim 1 further comprising a variable resistor between said current supply means and said electrode effective to control the magnitude of the current.
6. The system of claim 1 wherein said current supply means comprises an electrode having sufficient electrochemical potential with respect to the working electrode to discharge the charged working electrode when both electrodes are contacted with a physiological medium.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US673,522 | 1984-11-19 | ||
| US06/673,522 US4585652A (en) | 1984-11-19 | 1984-11-19 | Electrochemical controlled release drug delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1266887A true CA1266887A (en) | 1990-03-20 |
Family
ID=24702999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000495562A Expired - Fee Related CA1266887A (en) | 1984-11-19 | 1985-11-18 | Electrochemical controlled release drug delivery system |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4585652A (en) |
| EP (1) | EP0182765B1 (en) |
| JP (1) | JPS61196967A (en) |
| AT (1) | ATE79745T1 (en) |
| CA (1) | CA1266887A (en) |
| DE (1) | DE3586560T2 (en) |
Families Citing this family (214)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0280155B1 (en) * | 1987-02-25 | 1992-05-20 | Hoechst Aktiengesellschaft | Microencapsulation of biologically active material |
| JP2907342B2 (en) * | 1988-01-29 | 1999-06-21 | ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア | Ion infiltration non-invasive sampling or delivery device |
| US5362307A (en) * | 1989-01-24 | 1994-11-08 | The Regents Of The University Of California | Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance |
| CA1322169C (en) * | 1988-04-22 | 1993-09-14 | Hiroshi Yamazaki | Ionic dressing of topical administration of drugs to wounds and burns |
| US5057072A (en) * | 1988-10-28 | 1991-10-15 | Medtronic, Inc. | Iontophoresis electrode |
| CA2001444C (en) * | 1988-10-28 | 2000-07-25 | Darrel F. Untereker | Iontophoresis electrode |
| IT1229203B (en) * | 1989-03-22 | 1991-07-25 | Bioresearch Spa | USE OF 5 METHYLTHETRAHYDROPHOLIC ACID, 5 FORMYLTHETRAHYDROPHOLIC ACID AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS IN THE FORM OF CONTROLLED RELEASE ACTIVE IN THE THERAPY OF MENTAL AND ORGANIC DISORDERS. |
| ES2082973T3 (en) * | 1990-03-30 | 1996-04-01 | Alza Corp | DEVICE FOR PHARMACEUTICAL IONTOPHORETICAL ADMINISTRATION. |
| US5098417A (en) * | 1990-04-12 | 1992-03-24 | Ricoh Kyosan, Inc. | Cellulosic wound dressing with an active agent ionically absorbed thereon |
| US5431625A (en) * | 1991-02-01 | 1995-07-11 | Empi, Inc. | Iontophoresis electronic device having a ramped output current |
| US5208154A (en) * | 1991-04-08 | 1993-05-04 | The United States Of America As Represented By The Department Of Energy | Reversibly immobilized biological materials in monolayer films on electrodes |
| US5356632A (en) * | 1991-09-12 | 1994-10-18 | S.I. Scientific Innovations Ltd. | Transdermal drug delivery device |
| WO1993005680A1 (en) * | 1991-09-13 | 1993-04-01 | Gillette Canada Inc. | Polymeric particles for dental applications |
| CA2087087C (en) * | 1992-01-22 | 2000-07-18 | Burton H. Sage, Jr. | Molecules for iontophoretic delivery |
| US5272217A (en) * | 1992-03-12 | 1993-12-21 | Regents Of The University Of Minnesota | Anisotropic polymers |
| US5429822A (en) * | 1992-03-13 | 1995-07-04 | Cambridge Scientific, Inc. | Biodegradable bursting release system |
| US5423956A (en) * | 1993-07-01 | 1995-06-13 | Regents Of The University Of Minnesota | Electrochemical process for the production of conducting polymer fibers |
| US5536263A (en) * | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
| US5871460A (en) * | 1994-04-08 | 1999-02-16 | Alza Corporation | Electrotransport system with ion exchange material providing enhanced drug delivery |
| WO1995027530A1 (en) * | 1994-04-08 | 1995-10-19 | Alza Corporation | Electrotransport system with ion exchange competitive ion capture |
| EP0773975A4 (en) * | 1994-08-04 | 1998-06-10 | Gordon George Wallace | Conducting electroactive biomaterials |
| US5551953A (en) * | 1994-10-31 | 1996-09-03 | Alza Corporation | Electrotransport system with remote telemetry link |
| US5861431A (en) * | 1995-06-07 | 1999-01-19 | Iotek, Inc. | Incontinence treatment |
| US5635209A (en) * | 1995-10-31 | 1997-06-03 | Vintage Pharmaceuticals, Inc. | Stabilized composition of levothyroxine sodium medication and method for its production |
| US5605616A (en) * | 1995-11-06 | 1997-02-25 | Versicor, Inc. | Reversible charge-based sequestration on solid support |
| WO1997027844A1 (en) | 1996-01-30 | 1997-08-07 | Novagent Oy | Composition for transdermal delivery of drugs |
| FI962461A (en) * | 1996-06-13 | 1997-12-14 | Novagent Oy | Method and pharmaceutical composition for transdermal drug delivery |
| US7070590B1 (en) * | 1996-07-02 | 2006-07-04 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| US5797898A (en) * | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| GB9702277D0 (en) * | 1997-02-04 | 1997-03-26 | Innes John Centre | Modified electrodes and their use |
| US6295474B1 (en) | 1998-03-13 | 2001-09-25 | Intermedics Inc. | Defibrillator housing with conductive polymer coating |
| US7713297B2 (en) | 1998-04-11 | 2010-05-11 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
| US7658727B1 (en) | 1998-04-20 | 2010-02-09 | Medtronic, Inc | Implantable medical device with enhanced biocompatibility and biostability |
| HUP0104383A3 (en) | 1998-11-02 | 2002-12-28 | Alza Corp Mountain View | Electrotransport drug delivery device including a compatible antimicrobial agent |
| EP1154691A4 (en) * | 1999-01-05 | 2004-07-07 | Massachusetts Eye & Ear Infirm | Targeted transscleral controlled release drug delivery to the retina and choroid |
| CA2362814A1 (en) * | 1999-02-18 | 2000-08-24 | Biovalve Technologies, Inc. | Electroactive pore |
| SE9902474D0 (en) * | 1999-06-30 | 1999-06-30 | Amersham Pharm Biotech Ab | Polymer valves |
| US6334859B1 (en) * | 1999-07-26 | 2002-01-01 | Zuli Holdings Ltd. | Subcutaneous apparatus and subcutaneous method for treating bodily tissues with electricity or medicaments |
| US6969382B2 (en) | 1999-07-26 | 2005-11-29 | Zuli Holdings, Ltd. | Method and apparatus for treating bodily tissues with medicinal substance |
| US6527762B1 (en) | 1999-08-18 | 2003-03-04 | Microchips, Inc. | Thermally-activated microchip chemical delivery devices |
| EP1229901B1 (en) * | 1999-11-17 | 2009-03-18 | Boston Scientific Limited | Microfabricated devices for the delivery of molecules into a carrier fluid |
| ATE323470T1 (en) * | 1999-12-10 | 2006-05-15 | Massachusetts Inst Technology | MICROCHIP DRUG DELIVERY SYSTEMS AND METHODS OF MANUFACTURING |
| WO2001041745A1 (en) | 1999-12-10 | 2001-06-14 | Lectec Corporation | Anti pruritic patch |
| US6454759B2 (en) * | 2000-02-28 | 2002-09-24 | The Regents Of The University Of California | Microfabricated injectable drug delivery system |
| ATE499988T1 (en) * | 2000-03-02 | 2011-03-15 | Microchips Inc | MICROMECHANICAL DEVICES AND METHODS FOR STORAGE AND SELECTIVE EXPOSURE OF CHEMICALS |
| WO2001091902A2 (en) | 2000-05-30 | 2001-12-06 | Massachusetts Institute Of Technology | Methods and devices for sealing microchip reservoir devices |
| AU2001283359A1 (en) * | 2000-08-14 | 2002-02-25 | Pharmacia Corporation | Drug release (delivery system) |
| AU2001283357A1 (en) * | 2000-08-14 | 2002-02-25 | Pharmacia Corporation | Drug delivery system with bilayer electrodes |
| AU2001283358A1 (en) * | 2000-08-14 | 2002-02-25 | Pharmacia Corporation | Drug delivery system with burst electrode |
| EP1339312B1 (en) * | 2000-10-10 | 2006-01-04 | Microchips, Inc. | Microchip reservoir devices using wireless transmission of power and data |
| AU2002224453A1 (en) | 2000-10-11 | 2002-04-22 | Microchips, Inc. | Microchip reservoir devices and facilitated corrosion of electrodes |
| US6632175B1 (en) * | 2000-11-08 | 2003-10-14 | Hewlett-Packard Development Company, L.P. | Swallowable data recorder capsule medical device |
| US6929636B1 (en) | 2000-11-08 | 2005-08-16 | Hewlett-Packard Development Company, L.P. | Internal drug dispenser capsule medical device |
| US6828062B2 (en) * | 2000-12-23 | 2004-12-07 | Santa Fe Science And Technology, Inc. | Long-lived conjugated polymer electrochemical devices incorporating ionic liquids |
| CA2432438C (en) | 2001-01-09 | 2011-04-26 | Microchips, Inc. | Flexible microchip devices for ophthalmic and other applications |
| US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
| US7067148B2 (en) * | 2001-02-15 | 2006-06-27 | King Pharmaceutical Research & Development, Inc. | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
| US20030224047A1 (en) * | 2001-02-15 | 2003-12-04 | Franz G. Andrew | Levothyroxine compositions and methods |
| US20030032675A1 (en) * | 2001-02-15 | 2003-02-13 | Franz G. Andrew | Manufacture of thyroid hormone tablets having consistent active moiety amounts |
| RU2290216C2 (en) * | 2001-04-04 | 2006-12-27 | Алза Корпорейшн | Transdermal electric-transport injection device with reservoir provided with anti-microbe compatible composition |
| WO2002089767A1 (en) | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
| US6973718B2 (en) * | 2001-05-30 | 2005-12-13 | Microchips, Inc. | Methods for conformal coating and sealing microchip reservoir devices |
| AU2002326304A1 (en) | 2001-05-31 | 2002-12-16 | Massachusetts Institute Of Technology | Microchip devices with improved reservoir opening |
| WO2003002243A2 (en) | 2001-06-27 | 2003-01-09 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
| ATE285756T1 (en) * | 2001-06-28 | 2005-01-15 | Microchips Inc | METHOD FOR HERMETIC SEALING MICROCHIP RESERVOIR DEVICES |
| US20030190349A1 (en) * | 2001-08-10 | 2003-10-09 | Franz G. Andrew | Methods of stabilizing pharmaceutical compositions |
| US20030180353A1 (en) * | 2001-08-10 | 2003-09-25 | Franz G. Andrew | Stabilized pharmaceutical compositions |
| US20030198667A1 (en) * | 2001-08-10 | 2003-10-23 | Franz Andrew G. | Methods of producing dispersible pharmaceutical compositions |
| US20030199586A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Unique levothyroxine aqueous materials |
| US20030198672A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique triidothyronine plasma AUC properties |
| US20030203967A1 (en) * | 2001-08-14 | 2003-10-30 | Franz G. Andrew | Levothyroxine compositions having unique Tmax properties |
| US20030195253A1 (en) * | 2001-08-14 | 2003-10-16 | Franz G. Andrew | Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration |
| US20030199587A1 (en) * | 2001-08-14 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique Cmax properties |
| US7101569B2 (en) | 2001-08-14 | 2006-09-05 | Franz G Andrew | Methods of administering levothyroxine pharmaceutical compositions |
| US6949763B2 (en) * | 2001-10-11 | 2005-09-27 | Marc Ovadia | Semiconductor and non-semiconductor non-diffusion-governed bioelectrodes |
| US20030190359A1 (en) * | 2001-10-29 | 2003-10-09 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
| EP1320267B1 (en) | 2001-12-14 | 2005-11-02 | STMicroelectronics S.r.l. | Method of compressing digital images acquired in colour filter array (CFA) format |
| WO2003092665A2 (en) * | 2002-05-02 | 2003-11-13 | Massachusetts Eye And Ear Infirmary | Ocular drug delivery systems and use thereof |
| US7687258B1 (en) * | 2002-05-20 | 2010-03-30 | Maki Wusi C | Direct electric biological agent detector |
| WO2004071487A2 (en) * | 2002-08-16 | 2004-08-26 | Microchips, Inc. | Controlled release device and method |
| WO2004026281A2 (en) * | 2002-09-23 | 2004-04-01 | Microchips, Inc. | Micro-reservoir osmotic release systems and microtube array device |
| WO2004073551A2 (en) * | 2003-02-18 | 2004-09-02 | Massachusetts Eye And Ear Infirmary | Transscleral drug delivery device and related methods |
| US6699282B1 (en) * | 2003-03-06 | 2004-03-02 | Gelsus Research And Consulting, Inc. | Method and apparatus for delivery of medication |
| US20050055014A1 (en) * | 2003-08-04 | 2005-03-10 | Coppeta Jonathan R. | Methods for accelerated release of material from a reservoir device |
| WO2005041767A2 (en) * | 2003-11-03 | 2005-05-12 | Microchips, Inc. | Medical device for sensing glucose |
| US7457667B2 (en) * | 2004-02-19 | 2008-11-25 | Silverleaf Medical Products, Inc. | Current producing surface for a wound dressing |
| US7662176B2 (en) * | 2004-02-19 | 2010-02-16 | Vomaris Innovations, Inc. | Footwear apparatus and methods of manufacture and use |
| WO2005084378A2 (en) * | 2004-03-05 | 2005-09-15 | Board Of Regents Of University Of Texas System | Material and device properties modification by electrochemical charge injection in the absence of contacting electrolyte for either local spatial or final states |
| US20050220439A1 (en) * | 2004-03-19 | 2005-10-06 | Carton Owen A | Interactive multimedia system and method |
| US7850676B2 (en) * | 2004-04-19 | 2010-12-14 | The Invention Science Fund I, Llc | System with a reservoir for perfusion management |
| US7998060B2 (en) * | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling delivery device |
| US8512219B2 (en) | 2004-04-19 | 2013-08-20 | The Invention Science Fund I, Llc | Bioelectromagnetic interface system |
| US8092549B2 (en) * | 2004-09-24 | 2012-01-10 | The Invention Science Fund I, Llc | Ciliated stent-like-system |
| US20070244520A1 (en) * | 2004-04-19 | 2007-10-18 | Searete Llc | Lumen-traveling biological interface device and method of use |
| US8337482B2 (en) | 2004-04-19 | 2012-12-25 | The Invention Science Fund I, Llc | System for perfusion management |
| US9011329B2 (en) * | 2004-04-19 | 2015-04-21 | Searete Llc | Lumenally-active device |
| US8024036B2 (en) | 2007-03-19 | 2011-09-20 | The Invention Science Fund I, Llc | Lumen-traveling biological interface device and method of use |
| US8000784B2 (en) | 2004-04-19 | 2011-08-16 | The Invention Science Fund I, Llc | Lumen-traveling device |
| US8361013B2 (en) * | 2004-04-19 | 2013-01-29 | The Invention Science Fund I, Llc | Telescoping perfusion management system |
| US8353896B2 (en) | 2004-04-19 | 2013-01-15 | The Invention Science Fund I, Llc | Controllable release nasal system |
| US20050267440A1 (en) * | 2004-06-01 | 2005-12-01 | Herman Stephen J | Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant |
| WO2006015299A2 (en) * | 2004-07-30 | 2006-02-09 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
| WO2006026768A1 (en) | 2004-09-01 | 2006-03-09 | Microchips, Inc. | Multi-cap reservoir devices for controlled release or exposure of reservoir contents |
| WO2006044795A2 (en) | 2004-10-14 | 2006-04-27 | Trustees Of Tufts College | Electrochemically degradable polymers |
| US20060095001A1 (en) * | 2004-10-29 | 2006-05-04 | Transcutaneous Technologies Inc. | Electrode and iontophoresis device |
| EP1807092B1 (en) | 2004-11-05 | 2016-09-07 | The Children's Hospital of Philadelphia | Biodegradable linkers for molecular therapies |
| WO2006055729A1 (en) * | 2004-11-16 | 2006-05-26 | Transcutaneous Technologies Inc. | Iontophoretic device and method for administering immune response-enhancing agents and compositions |
| US7488316B2 (en) * | 2005-01-25 | 2009-02-10 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
| US20080076975A1 (en) * | 2005-01-25 | 2008-03-27 | Microchips, Inc. | Method and implantable device with reservoir array for pre-clinical in vivo testing |
| CA2606038A1 (en) * | 2005-04-22 | 2006-10-26 | Ecpoint Medical Inc. | Dc tissue treatment |
| JP2006334164A (en) * | 2005-06-02 | 2006-12-14 | Transcutaneous Technologies Inc | Iontophoresis apparatus and method for controlling the same |
| JP2006346368A (en) * | 2005-06-20 | 2006-12-28 | Transcutaneous Technologies Inc | Iontophoresis apparatus and manufacturing method |
| CN101243316A (en) * | 2005-06-30 | 2008-08-13 | 阿普尔拉股份有限公司 | Porous composite electrode comprising conductive polymer |
| US20070175768A1 (en) * | 2005-06-30 | 2007-08-02 | Applera Corporation | Microfluidic systems including porous polymer electrodes |
| WO2007010900A1 (en) * | 2005-07-15 | 2007-01-25 | Transcu Ltd. | Percutaneous absorption patch with application position indicating function, and iontophoresis device |
| JP2007037868A (en) * | 2005-08-05 | 2007-02-15 | Transcutaneous Technologies Inc | Transdermal administration device and its controlling method |
| EP1913969A4 (en) * | 2005-08-08 | 2009-12-02 | Tti Ellebeau Inc | Iontophoresis apparatus |
| US8295922B2 (en) * | 2005-08-08 | 2012-10-23 | Tti Ellebeau, Inc. | Iontophoresis device |
| US8386030B2 (en) * | 2005-08-08 | 2013-02-26 | Tti Ellebeau, Inc. | Iontophoresis device |
| US20070060860A1 (en) * | 2005-08-18 | 2007-03-15 | Transcutaneous Technologies Inc. | Iontophoresis device |
| US20070048362A1 (en) * | 2005-08-29 | 2007-03-01 | Transcutaneous Technologies Inc. | General purpose electrolyte solution composition for iontophoresis |
| US8005526B2 (en) * | 2005-08-31 | 2011-08-23 | The Regents Of The University Of Michigan | Biologically integrated electrode devices |
| US9084546B2 (en) | 2005-08-31 | 2015-07-21 | The Regents Of The University Of Michigan | Co-electrodeposited hydrogel-conducting polymer electrodes for biomedical applications |
| US20100030128A1 (en) * | 2005-09-06 | 2010-02-04 | Kazuma Mitsuguchi | Iontophoresis device |
| US20070112294A1 (en) * | 2005-09-14 | 2007-05-17 | Transcutaneous Technologies Inc. | Iontophoresis device |
| RU2008114490A (en) * | 2005-09-15 | 2009-10-20 | ТиТиАй ЭЛЛЕБО, ИНК. (JP) | STEM TYPE IONTOPHORESIS DEVICE |
| JPWO2007032423A1 (en) * | 2005-09-16 | 2009-03-19 | Ｔｔｉ・エルビュー株式会社 | Catheter-type iontophoresis device |
| US20070071807A1 (en) * | 2005-09-28 | 2007-03-29 | Hidero Akiyama | Capsule-type drug-releasing device and capsule-type drug-releasing device system |
| WO2007037324A1 (en) * | 2005-09-28 | 2007-04-05 | Transcu Ltd. | Dry electrode construct for iontophoresis |
| WO2007041322A2 (en) * | 2005-09-30 | 2007-04-12 | Tti Ellebeau, Inc. | Iontophoretic delivery of active agents conjugated to nanoparticles |
| JP2009509656A (en) * | 2005-09-30 | 2009-03-12 | Ｔｔｉ・エルビュー株式会社 | Method and system for detecting malfunction in an iontophoresis device delivering an active substance to a biological interface |
| US20070078445A1 (en) * | 2005-09-30 | 2007-04-05 | Curt Malloy | Synchronization apparatus and method for iontophoresis device to deliver active agents to biological interfaces |
| EP1941929A1 (en) * | 2005-09-30 | 2008-07-09 | Tti Ellebeau, Inc. | Electrode structure for iontophoresis comprising shape memory separator, and iontophoresis apparatus comprising the same |
| US20070078376A1 (en) * | 2005-09-30 | 2007-04-05 | Smith Gregory A | Functionalized microneedles transdermal drug delivery systems, devices, and methods |
| US20070232983A1 (en) * | 2005-09-30 | 2007-10-04 | Smith Gregory A | Handheld apparatus to deliver active agents to biological interfaces |
| WO2007037476A1 (en) * | 2005-09-30 | 2007-04-05 | Tti Ellebeau, Inc. | Iontophoresis apparatus capable of controlling dose and timing of administration of sleep inducer and analeptic agent |
| US20070197955A1 (en) * | 2005-10-12 | 2007-08-23 | Transcutaneous Technologies Inc. | Mucous membrane adhesion-type iontophoresis device |
| WO2007079116A1 (en) * | 2005-12-28 | 2007-07-12 | Tti Ellebeau, Inc. | Electroosmotic pump apparatus and method to deliver active agents to biological interfaces |
| WO2007079190A2 (en) * | 2005-12-29 | 2007-07-12 | Tti Ellebeau, Inc. | Device and method for enhancing immune response by electrical stimulation |
| WO2007079189A2 (en) * | 2005-12-30 | 2007-07-12 | Tti Ellebeau, Inc. | System and method for remote based control of an iontophoresis device |
| US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
| US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
| US8036738B2 (en) | 2006-03-14 | 2011-10-11 | New Jersey Institute Of Technology | Iontophoretic transdermal drug delivery system based on conductive polyaniline membrane |
| US20070224235A1 (en) | 2006-03-24 | 2007-09-27 | Barron Tenney | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
| US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
| WO2007123707A1 (en) * | 2006-03-30 | 2007-11-01 | Tti Ellebeau, Inc. | Controlled release membrane and methods of use |
| US20120035439A1 (en) | 2006-04-12 | 2012-02-09 | Bran Ferren | Map-based navigation of a body tube tree by a lumen traveling device |
| US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
| US20070275035A1 (en) * | 2006-05-24 | 2007-11-29 | Microchips, Inc. | Minimally Invasive Medical Implant Devices for Controlled Drug Delivery |
| WO2007137802A2 (en) * | 2006-05-26 | 2007-12-06 | Micromuscle Ab | Device and method for controlled delivery of chemical substances |
| US20090209899A1 (en) | 2006-06-15 | 2009-08-20 | Harry Unger | Delivery system and process |
| US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
| WO2008002778A2 (en) | 2006-06-29 | 2008-01-03 | Boston Scientific Limited | Medical devices with selective coating |
| WO2008017028A2 (en) | 2006-08-02 | 2008-02-07 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
| US8936794B2 (en) * | 2006-08-25 | 2015-01-20 | The Regents Of The University Of Michigan | Conducting polymer nanotube actuators for precisely controlled release of medicine and bioactive molecules |
| WO2008030497A2 (en) * | 2006-09-05 | 2008-03-13 | Tti Ellebeau, Inc. | Transdermal drug delivery systems, devices, and methods using inductive power supplies |
| WO2008033711A2 (en) | 2006-09-14 | 2008-03-20 | Boston Scientific Limited | Medical devices with drug-eluting coating |
| JP2010503489A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
| JP2010503485A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Medical device and method for manufacturing the same |
| ES2368125T3 (en) | 2006-09-15 | 2011-11-14 | Boston Scientific Scimed, Inc. | BIOEROSIONABLE ENDOPROOTHESIS WITH BIOESTABLE INORGANIC LAYERS. |
| US8057534B2 (en) * | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
| CA2663762A1 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
| US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
| WO2008067409A2 (en) * | 2006-11-28 | 2008-06-05 | Polyplus Battery Company | Protected lithium electrodes for electro-transport drug delivery |
| US20080122582A1 (en) * | 2006-11-29 | 2008-05-29 | Texas Instruments Incorporated | Location Based Portable Device Feature Disabler |
| EP2061551A2 (en) * | 2006-12-01 | 2009-05-27 | TTI ellebeau, Inc. | Systems, devices, and methods for powering and/or controlling devices, for instance transdermal delivery devices |
| EP2277563B1 (en) | 2006-12-28 | 2014-06-25 | Boston Scientific Limited | Bioerodible endoprostheses and method of making the same |
| US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
| US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
| US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
| JP5489988B2 (en) * | 2007-05-18 | 2014-05-14 | Ｔｔｉ・エルビュー株式会社 | Transdermal delivery device ensuring improved release of active ingredients to the biological interface |
| US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
| EP1997952B1 (en) * | 2007-05-29 | 2013-08-07 | Textilforschungsinstitut Thüringen-Vogtland e.V. | Textile structure for a transdermal active ingredient reservoir |
| DE102008025525A1 (en) * | 2007-05-29 | 2008-12-18 | Textilforschungsinstitut Thüringen-Vogtland e.V. | Electrically conductive thread for active ingredient storage and release, involves metallizing electrical nonconductive thread filament, and applying loading on metallized thread filament |
| ES2395877T3 (en) * | 2007-06-19 | 2013-02-15 | Rynel, Inc. | Materials comprising water soluble polymer particles and methods for preparing and using them |
| US20090005824A1 (en) * | 2007-06-29 | 2009-01-01 | Polyplus Battery Company | Electrotransport devices, methods and drug electrode assemblies |
| US20090012446A1 (en) * | 2007-07-03 | 2009-01-08 | Xinyan Cui | Devices, systems and methods for release of chemical agents |
| US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
| US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
| JP2010533563A (en) | 2007-07-19 | 2010-10-28 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adsorption inhibiting surface |
| US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
| US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
| US8221822B2 (en) | 2007-07-31 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
| JP2010535541A (en) | 2007-08-03 | 2010-11-25 | ボストン サイエンティフィック リミテッド | Coating for medical devices with large surface area |
| US20090069740A1 (en) * | 2007-09-07 | 2009-03-12 | Polyplus Battery Company | Protected donor electrodes for electro-transport drug delivery |
| US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
| US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
| US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
| US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
| WO2009100394A2 (en) * | 2008-02-08 | 2009-08-13 | Terumo Kabushiki Kaisha | Device for local intraluminal transport of a biologically and physiologically active agent |
| JP5581311B2 (en) | 2008-04-22 | 2014-08-27 | ボストン サイエンティフィック サイムド，インコーポレイテッド | MEDICAL DEVICE HAVING INORGANIC MATERIAL COATING AND MANUFACTURING METHOD THEREOF |
| WO2009132176A2 (en) | 2008-04-24 | 2009-10-29 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
| US20090292325A1 (en) * | 2008-05-02 | 2009-11-26 | Cederna Paul S | Hybrid bioelectrical interface device |
| US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
| US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
| WO2009155328A2 (en) | 2008-06-18 | 2009-12-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
| WO2009155405A1 (en) * | 2008-06-20 | 2009-12-23 | Boston Scientific Scimed, Inc. | Medical devices employing conductive polymers for delivery of therapeutic agents |
| US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
| EP2326360A2 (en) * | 2008-08-22 | 2011-06-01 | Boston Scientific Scimed, Inc. | Medical devices having a coating for electromagnetically-controlled release of therapeutic agents |
| CA2736495A1 (en) * | 2008-09-10 | 2010-03-18 | Gregory A. Smith | Apparatus and method to dispense hpc-based viscous liquids into porous substrates, e.g., continuous web-based process |
| US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
| US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
| US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
| US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
| US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
| TW201121604A (en) * | 2009-06-09 | 2011-07-01 | Tti Ellebeau Inc | Long life high capacity electrode, device, and method of manufacture |
| US8744568B2 (en) * | 2009-12-22 | 2014-06-03 | Boston Scientific Scimed, Inc. | Medical device with electroactive polymer powered by photovoltaic cell |
| WO2011119573A1 (en) | 2010-03-23 | 2011-09-29 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
| US9808616B2 (en) | 2011-01-14 | 2017-11-07 | The Regents Of The University Of Michigan | Regenerative peripheral nerve interface |
| US9713702B2 (en) | 2011-03-14 | 2017-07-25 | The Board Of Trustee Of The Leland Stanford Junior University | Methods of electric field induced delivery of compounds, compositions used in delivery, and systems of delivery |
| WO2014048456A1 (en) | 2012-09-25 | 2014-04-03 | Neurotech S.A. | Device for electrochemically releasing a composition in a controlled manner |
| DK3030286T3 (en) | 2013-08-05 | 2019-11-11 | Cam Med Llc | COMFORTABLE PATCH PUMP |
| US10314725B2 (en) | 2014-11-13 | 2019-06-11 | The Regents Of The University Of Michigan | Method for amplifying signals from individual nerve fascicles |
| WO2019068288A1 (en) * | 2017-10-04 | 2019-04-11 | Berlimed International Research Gmbh | Product containing active substance and active substance matrix for transdermal active substance delivery and production and use thereof and active substance matrix and production and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3991755A (en) * | 1973-07-27 | 1976-11-16 | Medicon, Inc. | Iontophoresis apparatus for applying local anesthetics |
| DE2626294C3 (en) * | 1976-06-11 | 1980-01-10 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantable dosing device |
| EP0045142B1 (en) * | 1980-07-24 | 1985-03-27 | The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and | Adsorption onto charcoal cloth |
| EP0060452B1 (en) * | 1981-03-05 | 1985-10-23 | Medtronic, Inc. | Iontophoretic device |
| US4506680A (en) * | 1983-03-17 | 1985-03-26 | Medtronic, Inc. | Drug dispensing body implantable lead |
-
1984
- 1984-11-19 US US06/673,522 patent/US4585652A/en not_active Expired - Fee Related
-
1985
- 1985-11-15 EP EP85850366A patent/EP0182765B1/en not_active Expired - Lifetime
- 1985-11-15 AT AT85850366T patent/ATE79745T1/en not_active IP Right Cessation
- 1985-11-15 DE DE8585850366T patent/DE3586560T2/en not_active Expired - Fee Related
- 1985-11-18 CA CA000495562A patent/CA1266887A/en not_active Expired - Fee Related
- 1985-11-18 JP JP60256823A patent/JPS61196967A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| EP0182765A3 (en) | 1989-02-01 |
| US4585652A (en) | 1986-04-29 |
| EP0182765B1 (en) | 1992-08-26 |
| ATE79745T1 (en) | 1992-09-15 |
| JPH0345661B2 (en) | 1991-07-11 |
| DE3586560T2 (en) | 1993-01-14 |
| DE3586560D1 (en) | 1992-10-01 |
| JPS61196967A (en) | 1986-09-01 |
| EP0182765A2 (en) | 1986-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1266887A (en) | Electrochemical controlled release drug delivery system | |
| US20020022826A1 (en) | Burst electrode | |
| Phipps et al. | Iontophoretic delivery model inorganic and drug ions | |
| JP2939550B2 (en) | Iontophoresis electrode | |
| JP4054890B2 (en) | Apparatus and method for drug administration by iontophoresis | |
| US5057072A (en) | Iontophoresis electrode | |
| US5084008A (en) | Iontophoresis electrode | |
| EP1233795B1 (en) | Electropolymerizable monomers and polymeric coatings on implantable devices | |
| US5320731A (en) | Iontophoresis device for transcutaneous administration of a given total quantity of an active principle to a subject | |
| Miller et al. | Electrochemically controlled release | |
| JPH09511664A (en) | Electrotransport system with enhanced drug delivery | |
| JP2006341107A (en) | Iontophoresis device for transcutaneous delivery of active ingredient anionic oligosaccharide-based | |
| EP2554365A1 (en) | Porous structure provided with pattern that is composed of conductive polymer, and method for producing same | |
| EP0457849B1 (en) | Electrotransport adhesive | |
| EP0959941B1 (en) | Electro-release systems | |
| Ryan et al. | Formation of polypyrrole with dexamethasone as a dopant: Its cation and anion exchange properties | |
| US8252045B2 (en) | Drug delivery from electroactive molecularly imprinted polymer | |
| Shinohara et al. | Electrically stimulated release of neurotransmitter from a conducting polymer thin film on the model of a synapse | |
| JPH10505254A (en) | Ion osmosis device having at least one electrode assembly including a reversible composite electrode | |
| Miller | Electrochemically Controlled Release of Ions from Polymers of Ions from Polymers | |
| JP2000017488A (en) | Production of polymer film | |
| Phipps et al. | IONTOPHORETIC DRUG DELIVERY: ADVANTAGES AND LIMITATIONS | |
| Smith | Electrochemical transdermal drug delivery | |
| Yaoita et al. | Electrochemical Manipulation of Single Cell with a Microelectrode | |
| AU3260000A (en) | Electro-release systems, modified electrodes and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |